What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a ...

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

An argument at a Cumberland Farms. A meeting at a Raynham Wendy's. License plate readers. How police homed in on a suspect in ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies.

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect its monopoly on multiple myeloma medicine Pomalyst, BMS is back in court, ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast ...

NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months ...

Bristol Myers to Acquire Karuna, a Neuroscience Drugmaker, for $14 Billion The deal is a bet on the growing market for psychiatric and neurological drugs.

(Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its older drugs, sending its share ...

Shares of Bristol Myers Squibb Co. BMY slipped 1.55% to $46.88 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.58% ...

Bristol Myers (BMY) Squibb announced results from POETYK PsA-1 and POETYK PsA-2, the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis ...